theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.